Scarica l'app Stockscreener
67.03
0.22%
0.15
Dopo l'orario di chiusura:
67.32
0.29
+0.43%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HALO Giù?
Forum
Previsione
Halozyme Therapeutics Inc Borsa (HALO) Ultime notizie
Is Halozyme Therapeutics Inc. stock attractive for growth ETFs2025 EndofYear Setup & Daily Profit Focused Screening - Trung tâm Dự báo KTTV quốc gia
How buybacks impact Halozyme Therapeutics Inc. stock value2025 Price Action Summary & Short-Term High Return Strategies - Trung tâm Dự báo KTTV quốc gia
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock - sharewise.com
Halozyme Acquires Elektrofi to Enhance Drug Delivery - MSN
Is Halozyme Therapeutics Inc. stock bottoming outCPI Data & Accurate Entry and Exit Point Alerts - newser.com
Halozyme Rallies Almost 40% YTD: How Should You Play the Stock? - sharewise.com
HC Wainwright & Co. Reiterates Halozyme Therapeutics (HALO) Buy Recommendation - Nasdaq
HALO: HC Wainwright & Co. Reiterates Buy Rating with $90 Target | HALO Stock News - GuruFocus
Leerink Partners Upgrades Halozyme Therapeutics (HALO) - Nasdaq
Leerink Partners upgrades Halozyme stock to Market Perform on lower Medicare exposure - Investing.com Nigeria
HALO Upgraded to Market Perform by Leerink Partners | HALO Stock News - GuruFocus
Halozyme Confirms Minimal Impact from Medicare Guidance - TipRanks
Halozyme Therapeutics issues statement on Medicare price negotiation guidance By Investing.com - Investing.com South Africa
Halozyme Therapeutics issues statement on Medicare price negotiation guidance - Investing.com
Halozyme Therapeutics (HALO) Stock Analysis: Robust Revenue Growth and Potential 18.56% Upside - DirectorsTalk Interviews
Janney Montgomery Scott LLC Sells 269,655 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
How to build a dashboard for Halozyme Therapeutics Inc. stockQuarterly Investment Review & Advanced Technical Signal Analysis - newser.com
Oak Ridge Investments LLC Trims Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Castellan Group Has $832,000 Stock Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics To $80? - Forbes
Zacks Research Issues Negative Estimate for HALO Earnings - MarketBeat
What technical models suggest about Halozyme Therapeutics Inc.’s comebackWall Street Watch & Long-Term Capital Growth Ideas - newser.com
Using data tools to time your Halozyme Therapeutics Inc. exitQuarterly Portfolio Report & Smart Money Movement Alerts - newser.com
Heatmap analysis for Halozyme Therapeutics Inc. and competitors2025 Support & Resistance & Fast Gain Swing Alerts - newser.com
Tectonic Advisors LLC Decreases Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Upgraded by Weiss Ratings to "Buy (B-)" Rating - MarketBeat
Key metrics from Halozyme Therapeutics Inc.’s quarterly data2025 Top Decliners & Short-Term Swing Trade Alerts - newser.com
Halozyme Therapeutics Inc Stock Analysis and ForecastProtective Put Strategies & Budget Friendly Portfolio - earlytimes.in
Can Elektrofi Acquisition Drive Halozyme's Long-Term Growth? - sharewise.com
Halozyme Therapeutics (NASDAQ:HALO) Downgraded by Zacks Research to Hold - MarketBeat
Zacks Research Analysts Increase Earnings Estimates for HALO - MarketBeat
Halozyme Therapeutics (HALO): What Recent Gains Reveal About Its Current Valuation - Yahoo
Halozyme Therapeutics Experiences Evaluation Revision Amidst Mixed Market Signals - Markets Mojo
Could Halozyme’s (HALO) New COO Appointment Signal a Shift in Operational Strategy or Partnerships? - Sahm
Halozyme Appoints New Chief Operating Officer - The Globe and Mail
Halozyme Therapeutics Names Cortney Caudill Chief Operating Officer - MarketScreener
Halozyme (HALO) Appoints New Chief Operating Officer - GuruFocus
Halozyme names Cortney Caudill as COO - TipRanks
Halozyme Therapeutics appoints Cortney Caudill as chief operating officer - Investing.com
Halozyme Therapeutics, Inc. Announces Appointment of Cortney Caudill as Senior Vice President and Chief Operating Officer, Effective October 1, 2025 - MarketScreener
Are Medical Stocks Lagging Armata Pharmaceuticals (ARMP) This Year? - Nasdaq
Pattern recognition hints at Halozyme Therapeutics Inc. upsideEarnings Overview Summary & Risk Managed Trade Strategies - newser.com
FY2025 EPS Forecast for Halozyme Therapeutics Cut by Analyst - MarketBeat
How geopolitical risks impact Halozyme Therapeutics Inc. (RV7) stock2025 Support & Resistance & Capital Protection Trading Alerts - newser.com
Will Halozyme Therapeutics Inc. (RV7) stock outperform global peersWeekly Stock Analysis & AI Based Trade Execution Alerts - newser.com
33,600 Shares in Halozyme Therapeutics, Inc. $HALO Acquired by LGT Fund Management Co Ltd. - MarketBeat
111 Capital Makes New Investment in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $1,380,600.00 in Stock - MarketBeat
Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 20,000 Shares of Stock - MarketBeat
Halozyme Announces Merger Agreement with Elektrofi - TipRanks
Halozyme Therapeutics says if deal is terminated under certain circumstances, co to pay Elektrofi reverse termination fee of $36 million - MarketScreener
Benchmark Sees More Upside for Halozyme Therapeutics (HALO), Hikes Price Target - MSN
Research Analysts Set Expectations for HALO FY2026 Earnings - MarketBeat
Institutional scanner results for Halozyme Therapeutics Inc.2025 Top Gainers & Daily Price Action Insights - newser.com
Is it too late to sell Halozyme Therapeutics Inc.Market Growth Summary & Free High Return Stock Watch Alerts - newser.com
Public Employees Retirement System of Ohio Acquires 38,049 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
1.84%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):